Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC

MET amplification or overexpression is a common resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) in the treatment of EGFR mutated non-small cell lung cancer (NSCLC). To precisely identify patients that could benefit from an additional MET blockade, histologic examination of immunohistochemically (IHC) stained tissue or fluorescence in-situ hybridization (FISH) are being used in clinical trials.